EME OD MD

Palonosetron is a second-generation selective antagonist of the serotonin 5-HT3 receptor, primarily used to prevent acute and delayed nausea and vomiting associated with moderately and highly emetogenic cancer chemotherapy, as well as postoperative nausea and vomiting in adults.[1] It is also indicated for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients aged 1 month to less than 17 years.[1] Administered as a single intravenous dose of 0.25 mg for chemotherapy-related indications or 0.075 mg for postoperative use, palonosetron offers a longer duration of action compared to first-generation 5-HT3 antagonists due to its approximately 40-hour half-life.[1][2]